The role of pramlintide for weight loss (Q37694145)

22 August 2017

1 reference

title

The role of pramlintide for weight loss (English)

1 reference

22 August 2017

Kaelen C Dunican

1

1 reference

22 August 2017

Nicole M Adams

series ordinal

2

1 reference

22 August 2017

Alicia R Desilets

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

17 February 2010

1 reference

Annals of Pharmacotherapy

22 August 2017

1 reference

22 August 2017

44

1 reference

22 August 2017

3

1 reference

22 August 2017

538-545

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

22 August 2017

1 reference

Medical Consequences of Obesity

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

21 January 2018

1 reference

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets

21 January 2018

1 reference

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

21 January 2018

1 reference

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.

21 January 2018

1 reference

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21 January 2018

1 reference

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight

21 January 2018

1 reference

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

21 January 2018

1 reference

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

21 January 2018

1 reference

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin

21 January 2018

1 reference

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

21 January 2018

1 reference

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

21 January 2018

1 reference

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

21 January 2018

1 reference

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

Overweight, obesity, and blood pressure: the effects of modest weight reduction

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M210

1 reference

22 August 2017

1 reference